Previous 10 | Next 10 |
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a con...
Processa Pharmaceuticals (NASDAQ:PCSA) said the first patient with advanced refractory gastrointestinal cancer was dosed in a maximum tolerated dose (MTD) phase 1b trial of next generation chemotherapy Capecitabine (a combination of PCS6422 and capecitabine). The company has amended the ...
Processa f ocuse s on i dentify ing the PCS6422 regimens to i ncrease c apecitabine potency while identifying the MTD of Next Generation Capecitabine The amended p rotocol will provi de a more precise ti...
Gainers: Checkmate Pharmaceuticals CMPI +333%. Petros Pharmaceuticals (PTPI) +55%. Axsome Therapeutics AXSM +23%. Avinger (AVGR) +11%. Processa Pharmaceuticals (PCSA) +10%. Losers: Lyra Therapeutics (LYRA) -16%. Diffusion Pharmaceuticals (DFFN) -15...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 ...
Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B market Expect t op l ine d ata at the end of 2022 HANOVER, MD, April 05, 2022 (GLOBE NEWSWIRE...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for 2021 year end....
The following slide deck was published by Processa Pharmaceuticals, Inc. in conjunction with this event. For further details see: Processa Pharmaceuticals (PCSA) Investor Presentation - Slideshow
Processa Pharmaceuticals, Inc. (PCSA) Q4 2021 Earnings Conference Call March 30, 2022 4:30 PM ET Company Participants Jim Stanker – Chief Financial Officer David Young – Chief Executive Officer Conference Call Participants Frank Brisebois – Oppenheimer Robin Garner ȁ...
Processa Pharmaceuticals press release (NASDAQ:PCSA): FY GAAP EPS of -$0.75 misses by $0.01. During the year ending on December 31, 2021 we increased our cash balance by $1.1 million compared to December 31, 2020. For further details see: Processa Pharmaceuticals GAAP EPS of -$0.75 miss...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...